Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
- PMID: 34854581
- PMCID: PMC8636760
- DOI: 10.4070/kcj.2021.0336
Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
Conflict of interest statement
The authors have no financial conflicts of interest.
Comment on
- Korean Circ J. 51(12):1001.
References
-
- Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323. - PubMed
-
- El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10:462–473. - PubMed
-
- Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997. - PubMed
-
- Stefanini GG, Holmes DR., Jr Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254–265. - PubMed
Publication types
LinkOut - more resources
Full Text Sources